Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.57 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647214 | 0.84 | KDR (0.72) | BRAFSRCKDRMAPK14MAPK13 | |
| SCHEMBL28709958 | 0.77 | PTGS2 (0.64) | BRAFSRCKDRMAPK14PTGS2 | |
| SCHEMBL1646570 | 0.77 | BRAF (0.62) | BRAFSRCKDRMAPK14MAPK13 | |
| SCHEMBL10368276 | 0.77 | SRC (0.62) | BRAFSRCKDRMAPK14PTGS2 | |
| SCHEMBL5463467 | 0.76 | MAPK13 (0.73) | BRAFSRCKDRMAPK14MAPK13 | |
| SCHEMBL1646508 | 0.76 | SRC (0.61) | BRAFSRCKDRMAPK14MAPK13 | |
| SCHEMBL1646015 | 0.73 | MAPK14 (0.59) | BRAFSRCKDRMAPK14MAPK13 | |
| SCHEMBL5698604 | 0.73 | CSNK1D (1.00) | BRAFSRCKDRMAPK14MAPK13 | |
| SCHEMBL5257540 | 0.73 | CSNK1D (1.00) | BRAFSRCKDRMAPK14MAPK13 | |
| SCHEMBL14839387 | 0.73 | BRAF (1.00) | BRAFSRCKDRMAPK14KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416123-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2016-08-16 | — | — | US | disclosed |
| US-9416123-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2016-08-16 | — | — | US | disclosed |
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| WO-2013046041-A1 | PYRIDINYLPYRAZOLES FOR USE AS KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | DCK, MAP3K2, MAP3K19 | BRAF 78/4885SRC 124/4885KDR 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.